Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 4, 1996, Pages 452-460

  Visser, W Hester ^b   Burggraaf, Jacobus ^b   Muller, Linda M ^b   Schoemaker, Rik C ^b   Fowler, Patricia A ^b   Cohen, Adam F ^b   Ferrari, Michel D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; SUMATRIPTAN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; FEMALE; HEADACHE; HUMAN; MALE; MIGRAINE; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIGRAINE DISORDERS; RECURRENCE; SUMATRIPTAN; VASOCONSTRICTOR AGENTS;

EID: 0029857086     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90202-7     Document Type: Article

References (23)

1. Ferrari MD, for The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-21.
2. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265: 2831-5.
3. Plosker GL, McTavish D. Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994;47:622-51.
4. Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci 1993;14:129-33.
5. 1 receptors in migraine pathophysiology and treatment. Eur J Neurol 1995;2: 5-21.
6. Visser WH, de Vriend RHM, Jaspers NMWH, Ferrari MD. Sumatriptan in clinical practice: a two-year review of 453 migraine patients. Neurology 1996;47: 46-51.
7. Visser WH, Jaspers NMWH, de Vriend RHM, Ferrari MD. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996;16:264-9.
8. Visser WH, de Vriend RHM, Jaspers NMWH, Ferrari MD. Sumatriptan nonresponders: a survey in 366 migraine patients. Headache 1996;36:471-5.
9. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991;31:291-4.
10. Scott AK. Sumatriptan: clinical pharmacokinetics. Clin Pharmacokinet 1994;27:337-44.
11. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995;47:543-8.
12. Cutler NR, Hussey EK, Sramek JJ, Clements BD, Paulsgrove LA, Busch MA, et al. Oral sumatriptan in pharmacokinetics in the migrainous state. Cephalalgia 1991;11 (suppl 11):222-3.
13. Humphrey PPA, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991;12:444-6.
14. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-11.
15. Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet 1991;338:13-7.
16. Caekebeke JFV, Zwetsloot CP, Jansen JC, Saxena PR, Ferrari MD. Sumatriptan increases the cranial blood flow velocity during migraine attacks: a transcranial Doppler study. In: Olesen J, editor. Migraine and other headaches: the vascular mechanisms. New York: Raven Press, 1991:331-4.
17. Caekebeke JFV, Ferrari MD, Zwetsloot CP, Jansen J, Saxena PR. Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology 1992;42:1522-6.
18. Caekebeke JFV, Saxena PR, Ferrari MD. Effect of sumatriptan on cranial blood flow velocity during and between migraine attacks. In: Oleson J, Saxena PR, editors. 5-Hydroxytryptamine mechanisms in primary headaches. New York: Raven Press, 1992:273-7.
19. Ferrari MD, Haan J, Blokland JAK, Arndt JW, Minnee P, Zwinderman AH, et al. Cerebral blood flow during migraine attacks without aura and effects of sumatriptan. Arch Neurol 1995;52:135-9.
20. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
21. Andrew PD, Birch HL, Phillpot DA. Determination of sumatriptan succinate in plasma and urine by high-performance liquid chromatography with electrochemical detection. J Pharm Sci 1993;82:73-6.
22. Lacey LF, Fowler PA. The clinical pharmacology of sumatriptan [abstract]. Cephalalgia 1993;13 (suppl 13):156.
23. Thomsen LL, Iversen HK, Olesen J. Cerebral blood flow velocities are reduced during attacks of unilateral migraine without aura. Cephalalgia 1995;15: 109-16.